← Back to patent-cliff list
WVE-006
Tier C — Watch / tradeWVE-006
Wave Life Sciences Ltd
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Nucleic acid drug
Type
Targets：SERPINA1, RNA
Indications (approved)：α1抗胰蛋白酶缺乏症
Regional status
US
Phase I
2023-12-06
EU
Phase II
2024-07-19
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of WVE-006?
Approved indications include: α1抗胰蛋白酶缺乏症.
When does the WVE-006 patent expire?
No public expiry year is available for WVE-006 yet; this page updates once verified.
How do I get a quote for WVE-006 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01